In today’s recent session, 1.88 million shares of the Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) have been traded, and its beta is 1.39. Most recently the company’s share price was $0.17, and it changed around -$0.05 or -19.41% from the last close, which brings the market valuation of the company to $3.35M. SNOA at last check was trading at a discount to its 52-week high of $1.02, offering almost -500.0% off that amount. The share price’s 52-week low was $0.12, which indicates that the recent value has risen by an impressive 29.41% since then. We note from Sonoma Pharmaceuticals Inc.’s average daily trading volume that its 10-day average is 2.54 million shares, with the 3-month average coming to 4.82 million.

Sonoma Pharmaceuticals Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended SNOA as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Sonoma Pharmaceuticals Inc. is expected to report earnings per share of -0.05 for the current quarter.

Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) trade information

Instantly SNOA has been showing red trend so far today with a performance of -19.41% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.2450 on recent trading dayincreased the stock’s daily price by 30.61%. The company’s shares are currently down -3.10% year-to-date, but still down -21.30% over the last five days. On the other hand, Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) is -53.50% down in the 30-day period. We can see from the shorts that 0.38 million shares have been sold at a short interest cover period of 0.27 day(s).

Sonoma Pharmaceuticals Inc. (SNOA) estimates and forecasts

Sonoma Pharmaceuticals Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 22.07 percent over the past six months and at a 47.37% annual growth rate that is well above the industry average of 20.00%. The year-over-year growth rate is expected to be 33.30%, up from the previous year.

Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 3.98M in revenue for the current quarter. 1 analysts expect Sonoma Pharmaceuticals Inc. to make 4.39M in revenue for the current ending quarter.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 47.04%.

SNOA Dividends

Sonoma Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released on 2024-Nov-11.

Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.97% of Sonoma Pharmaceuticals Inc. shares, and 2.14% of them are in the hands of institutional investors. The stock currently has a share float of 2.18%. Sonoma Pharmaceuticals Inc. stock is held by 20.0 institutions, with CITADEL ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 1.2504% of the shares, which is about 0.2 million shares worth $41412.0.

GEODE CAPITAL MANAGEMENT, LLC, with 0.5551% or 86644.0 shares worth $18385.0 as of 2024-06-30, holds the second largest percentage of outstanding shares.

Fidelity Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund were the top two Mutual Funds as of Jun 30, 2024 . The former held 79.95 shares worth $13598.0, making up 0.42% of all outstanding shares. On the other hand, Fidelity NASDAQ Composite Index Fund held roughly 4.97 shares worth around $846.0, which represents about 0.03% of the total shares outstanding.